{"id":3198,"date":"2018-03-27T10:10:07","date_gmt":"2018-03-27T14:10:07","guid":{"rendered":"http:\/\/sites.nd.edu\/entrepreneurlaw\/?p=3198"},"modified":"2018-03-27T13:24:12","modified_gmt":"2018-03-27T17:24:12","slug":"biotechnology-patents-are-not-deat","status":"publish","type":"post","link":"https:\/\/sites.nd.edu\/entrepreneurlaw\/2018\/03\/27\/biotechnology-patents-are-not-deat\/","title":{"rendered":"Biotechnology Patents Are Not Dead!"},"content":{"rendered":"<p>This <a href=\"https:\/\/www.genengnews.com\/gen-exclusives\/are-biotechnology-patents-dead\/77900698\">article<\/a> gives a nice overview over the development of the Supreme Court\u2019s position on the patentability of biotechnology since Chakrabarty in 1980. While it points out that the Supreme Court has stripped back some eligible subject matter, in particular with its decisions in Myriad and Sequenom, it concludes that patent protection remains a valuable part of a biotechnology company\u2019s business strategy.<\/p>\n<p>The article also presents arguments pro and against stronger patent protection in this area based on a economic rather than moral approach. It points out that proponents of stronger patent protection fear that the elimination of entire categories of patentable subject matter \u201creduces or eliminates the incentive to invest in development of new treatments and diagnostic methods.\u201d<\/p>\n<p>But on the other hand, others believe this development fosters competition and increases \u201cdevelopment of next-generation treatments resulting from modification of naturally occurring molecules.\u201d This group also argues that the trend in the diagnostic market, anyway, is toward using information technology and data mining platforms.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This article gives a nice overview over the development of the Supreme Court\u2019s position on the patentability of biotechnology since Chakrabarty in 1980. While it points out that the Supreme Court has stripped back some eligible subject matter, in particular &hellip; <a href=\"https:\/\/sites.nd.edu\/entrepreneurlaw\/2018\/03\/27\/biotechnology-patents-are-not-deat\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2887,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3198","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/sites.nd.edu\/entrepreneurlaw\/wp-json\/wp\/v2\/posts\/3198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.nd.edu\/entrepreneurlaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sites.nd.edu\/entrepreneurlaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sites.nd.edu\/entrepreneurlaw\/wp-json\/wp\/v2\/users\/2887"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.nd.edu\/entrepreneurlaw\/wp-json\/wp\/v2\/comments?post=3198"}],"version-history":[{"count":2,"href":"https:\/\/sites.nd.edu\/entrepreneurlaw\/wp-json\/wp\/v2\/posts\/3198\/revisions"}],"predecessor-version":[{"id":3215,"href":"https:\/\/sites.nd.edu\/entrepreneurlaw\/wp-json\/wp\/v2\/posts\/3198\/revisions\/3215"}],"wp:attachment":[{"href":"https:\/\/sites.nd.edu\/entrepreneurlaw\/wp-json\/wp\/v2\/media?parent=3198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sites.nd.edu\/entrepreneurlaw\/wp-json\/wp\/v2\/categories?post=3198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sites.nd.edu\/entrepreneurlaw\/wp-json\/wp\/v2\/tags?post=3198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}